XORTX (NASDAQ: XRTX) moves 1-for-5 share consolidation to April 6

Rhea-AI Filing Summary

XORTX Therapeutics Inc. has postponed the effective date of its planned share consolidation. The company now expects the 1-for-5 consolidation of its common shares to take effect on April 6, 2026 instead of March 27, 2026, and it remains subject to required approvals from the TSX Venture Exchange and Nasdaq Stock Exchange. XORTX is a late-stage clinical pharmaceutical company developing therapies for gout, autosomal dominant polycystic kidney disease, and kidney injury related to respiratory virus infections.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2026

Commission File Number: 001-40858

XORTX Therapeutics Inc.

3710 – 33rd Street NW, Calgary, Alberta, T2L 2M1

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		XORTX Therapeutics Inc.
		(Registrant)
Date: March 26, 2026		By:	/s/ Allen Davidoff
		Name:	Allen Davidoff
		Title:	Chief Executive Officer

EXHIBIT INDEX

99.1 News release dated March 26, 2026

 

EXHIBIT 99.1

XORTX Announces Change of Effective Date of Share Consolidation

CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, further to its news release of March 25, 2026, the Company has delayed the implementation of its share consolidation on the basis of one (1) new common share for every five (5) old common shares (the “Consolidation”) from March 27, 2026 to April 6, 2026, and remains subject to the receipt of all required approvals of the TSX Venture Exchange and Nasdaq Stock Exchange.

About XORTX Therapeutics Inc.

XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead program XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases. Additional information on XORTX is available at www.xortx.com.

 For more information, please contact:

Allen Davidoff, CEO	Nick Rigopulos, Director of Communications
adavidoff@xortx.com	nick@alpineequityadv.com
+1 403 455 7727	+1 617 901 0785

Forward Looking Statements

This press release contains express or implied forward-looking statements pursuant to applicable securities laws. These forward-looking statements include, but are not limited to, the Company's beliefs, plans, goals, objectives, expectations, assumptions, estimates, intentions, future performance, other statements that are not historical facts and statements identified by words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates” or words of similar meaning. These forward-looking statements and their implications are based on the current expectations of the management of XORTX only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks, uncertainties, and other factors include, but are not limited to, regulatory approvals, such as the TSXV; the ability to complete the Consolidation; the success and timing of our preclinical studies and clinical trials; the performance of third-party manufacturers and contract research organizations; our plans to develop and commercialize our product candidates; our plans to advance research in other kidney disease applications; and, our ability to obtain and maintain intellectual property protection for our product candidates. Except as otherwise required by applicable law and stock exchange rules, XORTX undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading “Risk Factors” in XORTX’s Annual Report on Form 20-F filed with the SEC, which is available on the SEC's website, www.sec.gov (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on www.sedarplus.ca.

FAQ

What did XORTX Therapeutics Inc. (XRTX) change about its share consolidation?

XORTX delayed the effective date of its planned share consolidation. The 1-for-5 consolidation of common shares is now expected to take effect on April 6, 2026 instead of March 27, 2026, subject to required stock exchange approvals.

What is the share consolidation ratio for XORTX Therapeutics Inc. (XRTX)?

XORTX plans a share consolidation on the basis of one new common share for every five old common shares. This 1-for-5 ratio reduces the number of outstanding shares while proportionally increasing the share price, without changing each shareholder’s overall economic interest.

When is XORTX Therapeutics Inc. (XRTX) share consolidation expected to become effective?

XORTX now targets April 6, 2026 as the effective date for its 1-for-5 share consolidation. This replaces the previously indicated date of March 27, 2026 and still depends on obtaining all necessary TSX Venture Exchange and Nasdaq approvals.

Are regulatory approvals still required for the XORTX (XRTX) share consolidation?

Yes. XORTX states the share consolidation remains subject to receipt of all required approvals from the TSX Venture Exchange and the Nasdaq Stock Exchange. The consolidation can only proceed once these regulatory and listing approvals have been granted.

What type of company is XORTX Therapeutics Inc. (XRTX)?

XORTX is a late-stage clinical pharmaceutical company. It is developing therapies targeting aberrant purine metabolism and xanthine oxidase for conditions including gout, autosomal dominant polycystic kidney disease, acute kidney injury related to respiratory viruses, and Type 2 diabetic nephropathy.

What drug programs are in XORTX Therapeutics Inc. (XRTX) pipeline?

XORTX highlights three clinically advanced programs: XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease, and XRx-101 for acute kidney and other organ injury from respiratory virus infections. It is also developing XRx-225, a pre-clinical program for Type 2 diabetic nephropathy.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 5.6 KB